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Molecular and Clinical
Characterization of a Claudin-Low
Subtype of Gastric Cancer
abstract
PurposeClaudin-lowmolecular subtypes have been identified in breast and bladder cancers and
are characterized by low expression of claudins, enrichment for epithelial-to-mesenchymal
transition (EMT), and tumor-initiating cell (TIC) features. We evaluated whether the
claudin-low subtype also exists in gastric cancer.
Materials andMethods Four hundred fifteen tumors from The Cancer Genome Atlas (TCGA)
gastric cancermRNAdata setwere clustered on the claudin, EMT, andTICgene sets to identify
claudin-low tumors. We derived a 24-gene predictor that classifies gastric cancer into claudin-
lowandnon–claudin-low subtypes.This predictorwas validatedwith theAsianCancerResearch
Group(ACRG)dataset.Wecharacterizedmolecularandclinical featuresof claudin-lowtumors.
ResultsWe identified 46 tumors that had consensus enrichment for claudin-low features inTCGA
data set. Claudin-low tumors were most commonly diffuse histologic type (82%) and originally
classifiedasTCGAgenomicallystable (GS)subtype(78%).ComparedwithGSsubtype,claudin-low
subtypehadsignificantactivationinRhofamilyofGTPasessignaling,whichappearstoplayakeyrole
in its EMTandTICproperties. In the ACRGdata set, 28 of 300 samples were classified as claudin-
low tumorsby the24-genepredictor andwerephenotypically similar to the initiallyderivedclaudin-
low tumors.Clinically, claudin-low subtypehad theworst overall survival.Of note, thehazard ratios
that compared claudin-low versus GS subtype were 2.10 (95%CI, 1.07 to 4.11) in TCGA and 2.32
(95% CI, 1.18 to 4.55) in the ACRG cohorts, with adjustment for age and pathologic stage.
Conclusion We identified a gastric claudin-low subtype that carries a poor prognosis likely
related to therapeutic resistance as a result of its EMT and TIC phenotypes.
Precis Oncol 00. © 2017 by American Society of Clinical Oncology
INTRODUCTION
Claudin-low tumors have been identified as a
molecular subtype originally in breast cancer
and more recently in bladder cancer on the
basis of gene expression profiling.1,2 These dis-
tinct tumors are characterized by the low ex-
pression of tight-junction claudins, enrichment
for epithelial-to-mesenchymal transition (EMT)
markers, and tumor-initiating cell (TIC) features.1,2
Clinically, claudin-low tumors, which lack lumi-
nal differentiation marker expression, are associ-
ated with poor prognosis compared with luminal
tumors.1,3
Similar to breast, bladder, and other types of
cancer, gastric cancer is a heterogeneous disease
and arises from multiple genetic and epigenetic
aberrations.Tobetter understand thebiology that
drives gastric cancer, molecular evaluation of
gastric cancer has been performed and has led
to the identification of key dysregulated pathways
and the development ofmolecular classifications.4
Gene expression–based classifiers were reported
by the Asian Cancer Research Group (ACRG)5
and by Lei et al.6 The ACRG divided gastric
cancer tumors into four subtypes (microsatellite
unstable [MSI], EMT, and tumor protein 53
active and inactive), and Lei et al classified gastric
cancer tumors into three subtypes (proliferative,
metabolic, and mesenchymal).
On the basis of an integrative analysis of molec-
ular profiling data, The Cancer Genome Atlas
(TCGA) proposed the following four molecular
subtypes of gastric cancer tumors: Epstein-Barr
virus (EBV) positive, MSI, chromosomally un-
stable (CIN), and genomically stable (GS).7 This
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EBV-positivity and then by MSI-high status; the
remaining tumors are distinguished by degree of
aneuploidy.GS subtype is less well characterized by
this decision tree because it is distinguished from
CIN just on the basis of the absence of extensive
somatic copy number aberrations. However, GS
subtype was found to have some notable features,
including enrichment of Lauren diffuse histologic
type and alterations in the genes associatedwith cell
adhesion and motility, such as CDH1 and RHOA
mutations and CLDN18-ARHGAP fusions. In ad-
dition, comparisons between TCGA and ACRG
classification systems revealed that TCGA GS was
enriched in ACRG EMT.5 These findings suggest
that some GS tumors share molecular characteris-
tics with claudin-low tumors. Therefore, we eval-




TCGA stomach adenocarcinoma (STAD) RNA
expression data set was downloaded from the











































Fig 1. Identification of
a claudin-low subtype
in gastric cancer. (A)
Unsupervised clustering of
The Cancer Genome Atlas
(TCGA) gastric cancer
samples. Samples were





signature, and a tumor-
initiating cell (TIC)
signature.
were filtered out. Missing values were imputed
using the k-nearest neighbor imputation method,
and gene expression values were median centered
across each gene.
Gene Expression Signatures
Tight-junction claudin, EMT, and TIC gene
signatures were used in the classification of a
claudin-low subtype. The set of claudins used
was identified by Herschkowitz et al.9 The bi-
directional Pan-Cancer EMT signature was de-
rived by Tan et al.10 The gastric cancer–specific
TIC signaturewas derived from thepublicly avail-
able Gene Expression Omnibus gene expression
data set (GSE53276). Genes were filtered for a
significant difference between the control and
tumorigenic cell line 60As6 using the significance
analysis of microarrays with a false discovery
rate , 0.01 and for their presence in TCGA
STADdata set.We identified a panel of 119 genes
that are upregulated in gastric cancer TICs (Data
Supplement). Proliferation and immune gene sig-
natures were derived by Hippo et al11 and Iglesia
et al,12 respectively.
Identification of a Claudin-Low Subtype
Data were clustered on the claudin, EMT, and
TIC gene sets using average linkage clustering
with a centered correlation similarity metric on
the Cluster 3.0 platform (Stanford University,
Stanford, CA). A conservative node with low-
claudin, high EMT-UP, low EMT-DOWN,
and high TIC gene sets was selected. SigClust2 R
software (Statistical Significance of Clustering 2)
was run on the node to perform a Gaussian distri-
bution analysis, which expands to the entire gene
set for each increasing node. Tumors identified
by SigClust2 were called claudin-low subtype re-
gardless of the original TCGA subtype call. Breast
cancer claudin predictions were also made on
the 415-sample TCGA STAD data set using the
distance-weighted discrimination claudin classifier,
which is based on the 807-gene signature provided
by Prat et al.1 We applied prediction analysis of
microarrays to the 415-sample TCGA STAD data
set to derive a gastric claudin-low or other subtype
classifier. A threshold of 10.9 was selected, which
gives a 24-gene predictor with an overall error rate
of 0.055. An independent set of 300 gastric cancer
samples from theACRGdata set (GeneExpression
OmnibusGSE62254) servedasavalidationset.The
data set was mean collapsed onto genes and then
median centered. The Data Supplement contains
additional details on methods.
RESULTS
Identification of a Claudin-Low Subtype in
Gastric Cancer
We performed unsupervised hierarchical clus-
tering on 415 gastric cancer samples from
TCGA data set using gene signatures represen-
tative of biologic characteristics known to define
the claudin-low subtype of breast and bladder
cancers.1,2This unsupervisedhierarchical cluster-
ing with these gene signatures revealed a distinct
cluster that had characteristics of claudin-low
tumors (Fig 1A, highlighted in red). To ensure
that the set of tumors within the presumed
claudin-low cluster were homogeneous and dis-
tinct from adjacent clusters of tumors, we
performed a Gaussian distribution analysis (Data
Supplement). This method identified a conserved
node of 46 tumors (11.1%) that had consensus
enrichment for claudin-low features, and these
tumors, therefore, were defined as claudin-low
subtype. Classification of the non–claudin-low
tumors (n = 369) was as follows: EBV, 31 tumors;
MSI, 79 tumors; CIN, 218 tumors; and GS, 41
tumors. As we hypothesized, claudin-low tumors
were primarily found in the diffuse histologic type
andTCGAGS subtype (Figs 1B and 1C). Because
the claudin-low tumors were identified originally
in breast cancer, we applied the previously defined
breast cancer–specific claudin-low classifier to
TCGA gastric cancer samples and found a signif-
icant enrichment (P, .001, Fisher’s exact test) of
the breast cancer–defined claudin-low tumors
within the gastric claudin-low cluster (Data Sup-
plement).This finding further supports thenotion
that claudin-low tumors exhibit features of pre-
viously defined claudin-low tumors.
Gene Expression Signature Analysis
Relative to TIC and stem-cell features, breast
cancer claudin-low tumors express low levels
of proliferation genes and are likely slower-
cycling tumors.1,3 We examined proliferation
gene expression of gastric cancer by subtype
using a previously reported gastric cancer–specific
proliferation signature.11 Expression of the
proliferation-associated genes in the claudin-
low subtype was lowest among all the subtypes
(Figs 2A and 2B). Despite the apparent similarity
to GS subtype, the claudin-low subtype expressed
significantly lower levels of proliferation genes
than GS subtype (P , .001, Bonferroni-
corrected pairwise t test). This finding supports
that the claudin-low subtype of gastric cancer is a
unique subtype with distinct biologic properties.
The tumors identified as
claudin-lowarehighlighted
in red on the dendogram (n
= 415). Bar graphs show the
classification of 46 claudin-
low tumors by (B) TCGA







Another notable feature of the claudin-low
subtype of breast and bladder cancers is high
expression of immune cell genes, including T
and B cells.1,2 To characterize the immune re-
sponse ingastric claudin-lowtumors,weevaluated
gene signatures associated with immune cells by
molecular subtype using previously defined sig-
natures that correspond to tumor-infiltrating im-
mune cells.12 Heat maps of immune signature
expression across the 415 samples in order by
subtype showed generally high expression in
EBV, claudin-low, and GS (Fig 3A). On the basis
of the z scores of the gene signature, expression of
all immune signatures other than the B-cell sig-
nature was highest in the EBV subtype (Data
Supplement).
To assess the level of active immunosuppression,
we examined the expression of a previously de-
fined panel of immune checkpoint molecules (im-
munosuppression signature)2 and found that it
was also highest in the EBV subtype (Fig 3B;Data
Supplement). This observation is in line with the
previous report by Strong et al.13 wherein EBV-
positive gastric carcinoma samples expressed
high levels of the cytotoxic T-cell and natural
killer cell inhibitor indoleamine-2,3-dioxygenase
1, which leads to the induction of immune toler-
ance to tumors despite the elevated immune cell
infiltration. Similar to the previous analysis of
bladder cancer, a clear correlation existed between
the immune signatures and the immunosuppres-
sion signature across all gastric cancer subtypes2
(Data Supplement).
The prognostic impact of tumor-immune infil-
trates, especially tumor-infiltrating lymphocytes
(TILs), has been reported in multiple tumor
types.14,15 For instance, the presence of CD8+
TILs was associated with favorable survival
outcomes.16-18 Some studies evaluated the prog-
nostic relevance of TILs in gastric cancer, but the
results were not consistent across them.19-21 We
performed Cox proportional hazards regression
modeling for each immune gene signature, in-
cluding immunosuppression signature, across all
tumors and within each subtype. None of the
signatures were prognostic in TCGA gastric can-
cer samples (data not shown).
We explored potential mechanisms of immune
response by examining predicted neoantigen bur-
den and levels of cytokines and chemokines
among subtypes.Neoantigens are alteredpeptides
derived from tumor-intrinsicmutant proteins that
can elicit antitumor T-cell responses. We pre-
dicted neoantigens using a previously described
bioinformatics pipeline that takes as input exome
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gene expression by gastric
cancer subtypes. (A) Heat
map of supervised
clustering of gastric cancer
subtypes across previously
identified proliferation-
associated genes (n = 415).
(B) Boxplot of proliferation
gene signature z scores
across gastric cancer










sequencing and mRNA sequencing data.2 A
strong correlation was found between predicted
neoantigen burden and the number of somatic
mutations (Pearson r = 0.895; P , .001; Data
Supplement). Not surprisingly, MSI subtype
had a significantly higher predicted neoantigen
burden than theother subtypes (Fig 3C).A level of
predicted neoantigen could not explain the
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ANOVA P < .001
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Kruskal-Wallis P < .001
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cancer subtypes. (A) Heat
maps of supervised
clustering of gastric cancer
difference in immune infiltration among subtypes
because the predicted neoantigen burdens of
EBV, claudin-low, and GS subtypes were lower
than that of CIN subtype and relatively similar to
one another (Fig 3D).
We next examined the relative expression of a
previously defined panel of cytokines and chemo-
kines by subtype2 and observed a strong correla-
tion between this expression signature and
multiple immune signatures, including immuno-
suppression signature (Data Supplement). EBV
and GS subtypes had a high level of cytokine and
chemokine expression (Fig 3E). The increased
production of proinflammatory cytokines and
chemokines may contribute to immune infiltrate
in these subtypes. Overall, claudin-low tumors
appeared to have a high level of immune infiltra-
tion but lacked active immunosuppression within
the tumor microenvironment.
Pathway Analysis
Given that claudin-low tumors were primarily
found in GS subtype, we performed ingenuity
pathway analysis (IPA) and gene set enrichment
analysis to understand the gene expression pat-
terns that differentiate claudin-low tumors from
non–claudin-low GS tumors. IPA revealed that
claudin-low subtype had significant activation in
Rho family of GTPases signaling and significant
inactivation in Rho guanine nucleotide dissocia-
tion inhibitor (GDI) signaling compared with GS
subtype (Fig 4). RhoA (a member of the Rho
family of GTPases) signaling has been reported
to promote cancer stem-cell–like phenotype in
diffuse-type gastric cancer.22 In addition, claudin-
low subtypehadhigher levels of actin cytoskeleton
and integrin signaling relative to signaling levels in
GS subtype. Furthermore, gene set enrichment
analysis demonstrated enrichment of cell motil-
ity and adhesion-associated pathways in claudin-
low subtype (Data Supplement). These observa-
tions are in keeping with the TIC and EMT
phenotypes, which are defining characteristics
of claudin-low tumors.
Mutation and Copy Number Alteration
Analysis
We next examined somatic mutations and copy
number alterations using TCGA data set to com-
pare genomic events of claudin-low subtype with
those of non–claudin-low GS subtype (Data Sup-
plement). TCGA network reported RHOA and
CDH1 mutations, and CLDN18-ARHGAP fu-
sions were enriched in GS subtype.7 We did not
observe significant differences in the frequency of
these genomic events between the two sub-
types (Data Supplement). However, the claudin-
low subtype had a higher prevalence of CD44,
GATA4, and GATA6 amplifications than the GS
subtype. CD44 is a gastric cancer stem-cell marker
and involved in cell adhesion and migration.23
GATA4 and GATA6 are transcription factors in-
volved in gastric cancer tumorigenesis as lineage-
survival oncogenes.24 Amplification of these genes
and their subsequent effects on signal transduction
and transcription may be partially responsible
for differences in gene expression between the
subtypes.
A 24-Gene Classifier Accurately Predicts
Claudin-Low Tumors
To define a minimal set of genes that could
accurately classify claudin-low gastric cancer, we
applied prediction analysis of microarrays to
TCGA STAD data set and derived a 24-gene
predictor (Data Supplement), which accurately
classifies gastric cancer into claudin-low and non–
claudin-low subtypes, with a training error rate of
0.15 and 0.04, respectively. To validate this pre-
dictor, we made claudin-low subtype calls on an
independent set of 300 gastric cancer samples
from the ACRG data set. We also made TCGA
subtype calls (EBV,MSI, CIN, or GS) on the 300
tumors by following TCGA classification. Tu-
mors identified by the claudin-low predictor were
called claudin-low subtype regardless of TCGA
subtype call. The claudin-low predictor identified
28 claudin-low tumors (9.3%) in the ACRG data
set. Non–claudin-low tumors (n = 272) were clas-
sified into the following subtypes: EBV, 17 tu-
mors;MSI, 63 tumors; CIN, 162 tumors; andGS,
30 tumors. We found that claudin-low subtype in
the ACRG data set was phenotypically similar
to the initially derived claudin-low subtype in the
discovery TCGA data set as measured by expres-
sionof the claudin, EMT, andTICgene signatures
(Data Supplement). As expected, claudin-low tu-
mors were enriched in the diffuse histologic type
(Data Supplement). Claudin-low tumors were pri-
marily found in the ACRG EMT subtype (25 of
28), and approximately one half of the ACRG
EMT tumors were classified as claudin-low sub-
type (25 of 44). This finding suggests that the
ACRG EMT subtype is also subdivided into
claudin-low and non–claudin-low subtypes.
Clinical Characteristics
Claudin-low tumors were characterized by youn-
ger age at diagnosis, with a median age of 58 years
inTCGAcohort and63years in theACRGcohort
subtypes across previously
identified immune
signatures (n =415). (B)Box
plot of immune suppression
gene signature z scores
across gastric cancer




(ANOVA). (C) and (D) Box
plots show the number of
predicted neoantigens with
a half-maximal inhibitory




Wallis exact test (n = 357).
(E)Box plot of cytokine and
chemokine signature z
scores across gastric cancer









associated T helper 1; MSI,
microsatellite unstable.
(Data Supplement). To assess prognostic signifi-
cance of claudin-low subtype, we conducted sur-
vival analysis by subtype by using TCGA and
ACRG cohorts. Unadjusted Kaplan-Meier sur-
vival analysis of TCGA STAD data set showed a
trend toward worse prognosis for claudin-low
subtype than for the other subtypes (Fig 5A). A
similar analysis on the ACRG data set revealed a
substantiallyworse prognosis for claudin-low sub-
type (Fig 5B). To further compare prognosis for
claudin-low subtype with GS subtype, with ad-
justment for potential confounders (age and path-
ologic stage), we performed Cox proportional
hazards regression modeling by setting GS type
as a reference group (Table 1). We observed that
claudin-low subtype had significantly worse
overall survival than GS subtype in both TCGA
(hazard ratio [HR], 2.10; 95% CIs, 1.07 to 4.11;
P = .031) and the ACRG (HR, 2.32; 95%CIs, 1.18
to 4.55; P = .015) cohorts. In addition, we assessed
a prognostic value of claudin-low subtype in
patients with stage III cancer because it was the
largest subgroup with the most equal distribution
of subtypes. This analysis also showed that the
claudin-low subtype was associated with worse
overall survival than the GS subtype in both
TCGA (HR, 3.11; 95% CI, 1.10 to 8.75;
P = .032) and the ACRG (HR, 3.67; 95% CI,
1.43 to 9.43; P = .007) cohorts. Similar HRs from
the two independent data sets suggest that
claudin-low subtype of gastric cancer has a poor














































































































































MSILog-rank P = .206
TCGA Overall Survival by Subtype
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expressed genes in claudin-
low subtype compared with
genomically stable (GS)
subtype. Bar graph of the
most significantly activated
(gold) or inactivated (blue)
signaling pathways in
claudin-low subtype
(n = 46) compared with






inhibited) with an overlap
P < 0.05 and an IPA
activation z score > 2.0
(or <22.0). GDI, guanine
nucleotide dissociation
inhibitor; NFAT, nuclear
factor of activated T cells.
Fig 5. Prognosis of
claudin-low tumors in (A)
The Cancer Genome Atlas




plots show overall survival
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We characterized the claudin-low subtype of gas-
tric cancer. Approximately 80% of claudin-low
tumors were originally classified as TCGA GS
subtype. Thus, we especially focused on compar-
ing molecular and clinical features of claudin-low
tumorswith thoseofnon–claudin-lowGStumors.
Claudin-low gastric cancer was defined by low
expression levels of tight-junction claudins, high
levels of EMT, and enrichment for TIC signa-
tures. In addition, compared with GS subtype,
claudin-low subtype had the lower expression of
proliferation signature, significant activation in
Rho family ofGTPases signaling, and enrichment
of cell motility and adhesion-associated pathways.
Furthermore, the claudin-low subtype conferred
significantly worse prognosis than the GS sub-
type, which had comparable survival to the CIN
and EBV subtypes. These observations support
the claim that claudin-low subtype is distinct from
GS subtype and warrants additional validation in
prospective studies.
We report a 24-gene classifier that accurately
classifies gastric cancer into claudin-low and non–
claudin-low subtypes.We applied this classifier to
the ACRG data set and identified 28 claudin-low
tumors that were phenotypically similar to the
initially derived claudin-low subtype in the dis-
covery data set. Claudin-low tumors were primar-
ily found in the ACRG EMT subtype (25 of 28).
This finding is keeping with the notion that high
expression of EMT signatures is one of the key
features thatdefine claudin-low tumorsbut is not a
sufficient condition because claudin-low tumors
are also characterized by low expression of clau-
dins and enrichment for TIC signatures. As a
result, only approximately one half of the ACRG
EMT tumors were classified as claudin-low sub-
type (25 of 44), which suggests that the claudin-
low tumors are a subpopulation of the ACRG
EMT subtype.
Poor prognosis in patients with gastric claudin-
low tumors likely is related to EMT and TIC
properties. The combined expression of EMT
and cancer stem-cell makers was reported to be
associated with aggressive clinical features, such
as vascular invasion and metastasis, and prog-
nostic of poorer disease-free and overall survival
in a study of 276 patients with gastric cancer.25
Moreover, EMT and/or stem-cell–like biologic
processes have been linked to resistance to
chemotherapy and radiation.26-28 The mecha-
nisms of therapeutic resistance include relative
quiescence, expression of ATP-binding cas-
sette transporters, an active DNA-repair ca-
pacity, and a resistance to apoptosis.29 Recent
work by Yoon et al22 demonstrated a role of
RhoA, a member of the Rho family of GTPases,
in gastric cancer stem-like cells (CSCs) for the
maintenance of EMT phenotypes and chemo-
therapy resistance. Inhibition of RhoA in dif-
fuse gastric CSCs blocked spheroid formation,
migration, and invasion. Furthermore, RhoA
pathway inhibition reversed chemoresistance
in diffuse gastric CSCs resistant to fluorouracil
and cisplatin. Of note, our IPA revealed that,
compared with GS subtype, the most sig-
nificantly activated and inactivated pathway
in claudin-low subtype were Rho family of
GTPases signaling and RhoGDI signaling, re-
spectively. GDIs are regulators of RhoGTPases
and prevent activation of GTPases by acting as
molecular chaperones.30 All things considered,
dysregulated Rho GTPase signaling appears to
play a key role in the biology of gastric claudin-
low tumors and contributes to the poor prog-
nosis. Given the chemoresistance in gastric
CSCs, a specific CSC-targeted therapy must
be used in conjunction with conventional che-
motherapy to improve the outcome of claudin-
low tumors. To this end, Yoon et al22 tested a
Rho-associated protein kinase inhibitor, fasudil,
because it is a major downstream effector of
RhoA. They showed that fasudil worked simi-
larly to direct RhoA inhibition with RhoA short
hairpin RNA in reversing the CSC pheno-
types and chemoresistance. In addition, fasudil
worked synergistically with cisplatin chemo-
therapy in xenograft models. Given that fasudil
Table 1. Cox Proportional Hazards Regression Modeling for Overall Survival (TCGA
and ACRG cohorts)
Cohort Hazard Ratio 95% CI P
TCGA (reference group = GS)
Claudin-low 2.10 1.07 to 4.11 .031
CIN 1.02 0.57 to 1.81 .961
EBV 1.01 0.44 to 2.28 .989
MSI 0.65 0.33 to 1.29 .216
ACRG (reference group = GS)
Claudin-low 2.32 1.18 to 4.55 .015
CIN 1.05 0.58 to 1.90 .879
EBV 0.82 0.35 to 1.93 .643
MSI 0.60 0.29 to 1.24 .169
NOTE. Adjusted for age and pathologic stage (n = 415 in TCGA cohort; n = 300 in the ACRG cohort).
Abbreviations: ACRG, Asian Cancer Research Group; CIN, chromosomally unstable; EBV, Epstein-
Barr virus; GS, genomically stable; MSI, microsatellite unstable; TCGA, The Cancer Genome Atlas.
is already approved in Japan for use in ce-
rebral vasospasm secondary to subarachnoid
hemorrhage,31 future studies that explore the
combination of fasudil and chemotherapy for
treatment of gastric claudin-low tumors will be
of great interest.
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